Toray Industries, Inc.

Hideaki Inada

Kuniaki Kawamura

Katsuhiko Iseki

Keiichi Okimura

Toshiaki Tanaka

Hiroshi Nagase

Tadaaki Ohgi

Koji Oshima

Eriko Aoki

Takashi Endoh

Tomohiko Suzuki

Tsutomu Suzuki

Munetaka Kunishima

Yoshitaka Yoshizawa

Tatsuya Fujita

Ayumi Takashina

Masato Sanosaka

Kyohei Koshimoto

A method produces a hairpin single-stranded RNA molecule capable of inhibiting expression of a target gene, the method including: (i) an annealing step of annealing a first single-stranded oligoRNA molecule and a second single-stranded oligoRNA molecule; and (ii) a ligation step of ligating 3′ end of the first single-stranded oligoRNA molecule and 5′ end of the second single-stranded oligoRNA molecule by an Rnl2 family ligase, wherein a sequence produced by ligating the first single-stranded oligoRNA molecule and the second single-stranded oligoRNA molecule includes a gene expression-inhibiting sequence for the target gene.

Method of producing hairpin single-stranded RNA molecule

A method produces a hairpin single-stranded RNA molecule capable of inhibiting expression of a target gene, including the step of reacting a first single-stranded oligo-RNA molecule represented by formula (I) with a second single-stranded oligo-RNA molecule represented by formula (II) in a mixed solvent including a buffer solution and a hydrophilic organic solvent in the presence of a dehydration condensation agent: 5′-Xc-Lx(I) and Lx-X—Y-Ly-Yc-3′ (II), wherein the dehydration condensation agent is selected from the group consisting of a triazine-based dehydration condensation agent, a uronium-based dehydration condensation agent including an N-hydroxy nitrogen-containing aromatic ring structure, a carbodiimide-based dehydration condensation agent, a 2-halopyridinium-based dehydration condensation agent, and a formamidinium-based dehydration condensation agent.

Method of producing hairpin single-stranded RNA molecules

A therapeutic agent for sepsis and various symptoms accompanying sepsis (such as septic shock, disseminated intravascular coagulation syndrome, adult respiratory distress syndrome and multiple organ dysfunction) is disclosed. The therapeutic agent for sepsis according to the present invention comprises as an effective ingredient an opioid &#x3ba; receptor agonist compound such as (&#x2212;)-17-(cyclopropylmethyl)-3,14&#x3b2;-dihydroxy-4,5&#x3b1;-epoxy-6&#x3b2;[N-methyl-trans-3-(3-furyl)acrylamide] oxide derivative. The opioid &#x3ba; receptor agonist compound may be administered as it is or in the form of a pharmaceutical composition prepared by mixing the compound with a known pharmaceutically acceptable acid, carrier or vehicle orally or parenterally.

Remedies for sepsis

Remedies for drug addiction

Growing community of inventors

Kamakura, Japan

Hideaki Inada